Clinical Trial Update: TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

View source ↗

Summary

The clinical trial NCT01349075 evaluating TheraSphere for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Hepatocellular Carcinoma | Status: COMPLETED